Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Advancing Cytogenetics with Optical Genome Mapping (OGM)

NextEdge Admin

19 Apr 2024

2 min 51 sec

Optical Genome Mapping (OGM) is transforming cytogenetics, thanks to Bionano Genomics’ innovation in genome analysis. OGM, with its advanced technology, diagnostic services, and software, offers a groundbreaking method to visualize and analyze chromosome structure with unparalleled precision and efficiency.

At its heart, OGM employs a sophisticated labeling system that attaches to specific DNA segments, creating unique barcodes based on dynamic label distances. As DNA molecules pass through ultra-thin nanochannels, a high-resolution camera captures continuous images, facilitating automatic and digital chromosomal content analysis. This data furnishes researchers with comprehensive insights into chromosomal abnormalities, spanning from large-scale deletions and duplications to subtle rearrangements and translocations.

A major advantage of OGM lies in its capacity to scrutinize extensive DNA stretches, reducing the need for fragmenting and manipulating genetic material. This safeguards DNA integrity, ensuring researchers obtain an accurate portrayal of chromosomal structure. Furthermore, OGM boasts resolution levels orders of magnitude higher than traditional techniques like karyotyping, enabling the detection of abnormalities with unprecedented detail and accuracy.

Recently, Bionano Genomics, Inc. (BNGO), partnered with Diagens, a Chinese assisted reproductive technology firm specializing in AI-driven cytogenetics. The collaboration aims to introduce a pioneering cytogenetic workflow merging OGM with AI chromosome karyotype analysis. This innovative approach targets the identification of pathogenic Structural Variants (SVs) linked to recurrent pregnancy loss and other significant genome variants affecting pregnancy outcomes and newborn development.

Having secured Class I registration and approval for Bionano’s OGM reagents from China’s National Medical Products Administration (NMPA), Diagens plans to register the Saphyr™ instrument for clinical use in reproductive health.

Diagens marks Bionano’s third OEM collaboration in China, alongside A-smart MedTech and Beijing Genome Precision Technology (BGPT). Both previous partnerships resulted in NMPA Class I registrations for Bionano’s reagents.